Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sequencing capacity ramp-ups, antibody pipeline milestones, and cash-burn assumptions make Twist Bioscience’s SEC disclosures uniquely complex. Locating gene-synthesis revenue mix in the Twist Bioscience annual report 10-K simplified filing or tracing collaboration updates buried in an 8-K often means scrolling through hundreds of pages. Stock Titan solves this pain point by turning dense biotechnology jargon into concise insights, giving you twist bioscience SEC filings explained simply without losing critical detail.
Our AI reads every document the instant it hits EDGAR, delivering Twist Bioscience Form 4 insider transactions real-time, red-flagging risk-factor changes, and extracting segment metrics into dashboards. Whether you’re searching for a twist bioscience quarterly earnings report 10-Q filing, a sudden twist bioscience 8-K material events explained, or the latest twist bioscience proxy statement executive compensation tables, the platform highlights exactly where the numbers live and what they mean. Smart tags link cash-flow shifts to R&D spending so you can perform twist bioscience earnings report filing analysis in minutes, not hours.
Need to monitor management moves before the next capital raise? Track every twist bioscience insider trading Form 4 transactions alert or dive deeper into twist bioscience executive stock transactions Form 4 to spot buying trends. From cost-of-goods disclosures that impact gross margin to litigation notes that could reshape IP value, our expert commentary keeps you ahead. If you’re focused on understanding Twist Bioscience SEC documents with AI, start here—comprehensive coverage, real-time updates, and plain-English explanations for every filing type.
Twist Bioscience Corp (TWST) reported a new equity award to its Chief Executive Officer and director, Emily M. Leproust. On 11/18/2025, she received 146,914 shares of common stock in the form of restricted stock units at a reported price of
The RSU grant vests over four years, with 1/16 of the total vesting on each quarterly anniversary of
Twist Bioscience Corp (TWST) reported a routine insider equity grant to its President and COO, Patrick John Finn. On 11/18/2025, he received 68,740 shares of common stock in the form of restricted stock units (RSUs) at a price of $0 per share. Following this grant, he beneficially owned 334,659 shares of Twist Bioscience common stock in total.
The RSU award vests over four years, with 1/16 of the RSUs vesting on each quarterly anniversary of November 20, 2025, subject to his continued service. This structure ties a portion of the executive’s compensation to the company’s long-term performance and his ongoing role.
Twist Bioscience Corp (TWST) reported that its Chief Financial Officer received a grant of 32,648 restricted stock units (RSUs) of common stock on 11/18/2025. The RSUs were recorded at a price of $0 because they are equity awards rather than open‑market purchases.
Following this grant, the CFO beneficially owns 143,656 shares of Twist Bioscience common stock in total. The RSU award vests over four years: 1/16 of the total RSUs vest on each quarterly anniversary of November 20, 2025, for a total vesting period of 48 months, as long as the executive remains in continuous service through each vesting date.
Twist Bioscience Corp (TWST) officer Dennis Cho reported a grant of 25,465 restricted stock units (RSUs) of common stock at a price of $0 per share. After this equity award, he beneficially owns 146,159 shares of Twist Bioscience common stock in total.
The RSU award vests over four years, with 1/16 of the RSUs vesting on each quarterly anniversary of November 20, 2025, for a total vesting period of 48 months, subject to his continuous service with the company. Cho serves as Senior Vice President, Chief Legal Officer & Corporate Secretary, and this Form 4 reflects routine insider equity compensation.
Twist Bioscience Corp. (TWST) reported an equity award to a senior executive. Officer Paula Green, the company’s SVP of Human Resources, received 26,200 shares of common stock in the form of a restricted stock unit (RSU) grant on 11/18/2025 at a stated price of $0, reflecting a compensatory award rather than an open‑market purchase.
The RSUs vest over four years, with 1/16 of the total vesting on each quarterly anniversary of November 20, 2025, subject to her continued service through each vesting date. Following this grant, Paula Green beneficially owns 168,387 shares of Twist Bioscience common stock, held directly.
Twist Bioscience Corp (TWST) reported a Form 4 for its Chief Accounting Officer, Robert F. Werner. On 11/18/2025, he received 16,324 shares of common stock through a restricted stock unit (RSU) award at a price of $0 per share, reflecting stock-based compensation rather than a market purchase.
After this grant, Werner beneficially owns 67,194 shares of Twist Bioscience common stock in direct ownership. The RSU award vests over time: 1/16 of the RSUs vest on each quarterly anniversary of November 20, 2024, for a total vesting period of 48 months, contingent on his continued service with the company.
Twist Bioscience Corp (TWST) director Jan Johannessen reported a stock sale in a Form 4 filing. On 11/18/2025, the reporting person sold 7,044 shares of Twist Bioscience common stock at a price of $24.77 per share, coded as a sale transaction ("S"). After this transaction, the director beneficially owned 14,859 shares of common stock in the company, held directly. The filing is made as an individual filing by one reporting person and is signed by an attorney-in-fact on behalf of Jan Johannessen.
Twist Bioscience Corporation files its annual report describing operations for the year ended September 30, 2025, highlighting growth in synthetic biology, next-generation sequencing tools and biopharma services. The company reported $376.6 million in revenue, including $215.1 million from healthcare, $93.2 million from chemicals/materials, $65.9 million from academic research and $2.4 million from food/agriculture.
Twist continues to scale its silicon-based DNA synthesis platform, expand Express gene and IgG offerings, and deepen its antibody discovery business. Despite revenue growth, it recorded a net loss of $77.7 million and an accumulated deficit of $1,319.6 million, reflecting ongoing investment in manufacturing, R&D and commercialization. As of September 30, 2025, Twist had 442 revenue-generating partnerships and a deal under which XOMA Royalty paid $15 million for 50% of future milestones and royalties from existing collaborations, while Twist retained all upfront and service revenue.
Twist Bioscience Corporation furnished an 8-K to announce financial results for its fiscal fourth quarter and full fiscal year ended September 30, 2025. The company issued a press release on November 14, 2025, and attached it as Exhibit 99.1 titled “Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2025 Financial Results.”
The disclosure was made under Item 2.02 (Results of Operations and Financial Condition) and is being furnished, not filed, meaning it is not subject to Section 18 liability and is not incorporated by reference unless specifically stated. Twist’s common stock trades on the Nasdaq Global Select Market under the symbol TWST.
Twist Bioscience (TWST) insider Dennis Cho reported a sale of 1,019 shares of common stock at $32.0794 on 11/03/2025. According to the filing, this was a mandated “sell to cover” tied to the vesting of Restricted Stock Units to satisfy tax withholding obligations, not a discretionary trade. Following the transaction, Cho beneficially owns 120,694 shares, held directly. His role is listed as Senior Vice President, Chief Legal Officer & Corporate Secretary.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
